IN2014CN00315A - - Google Patents

Info

Publication number
IN2014CN00315A
IN2014CN00315A IN315CHN2014A IN2014CN00315A IN 2014CN00315 A IN2014CN00315 A IN 2014CN00315A IN 315CHN2014 A IN315CHN2014 A IN 315CHN2014A IN 2014CN00315 A IN2014CN00315 A IN 2014CN00315A
Authority
IN
India
Prior art keywords
directed
methods
subject matter
disclosed subject
presently disclosed
Prior art date
Application number
Other languages
English (en)
Inventor
Peter Lacouture
De Rocha Marcelo Garcia
Daniel B Carr
Original Assignee
Hospira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospira Inc filed Critical Hospira Inc
Publication of IN2014CN00315A publication Critical patent/IN2014CN00315A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN315CHN2014 2011-07-20 2012-07-19 IN2014CN00315A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161509886P 2011-07-20 2011-07-20
PCT/US2012/047453 WO2013013076A1 (en) 2011-07-20 2012-07-19 Methods of treating pain

Publications (1)

Publication Number Publication Date
IN2014CN00315A true IN2014CN00315A (ja) 2015-04-03

Family

ID=47558482

Family Applications (1)

Application Number Title Priority Date Filing Date
IN315CHN2014 IN2014CN00315A (ja) 2011-07-20 2012-07-19

Country Status (16)

Country Link
US (1) US20140221490A1 (ja)
EP (2) EP3257505A1 (ja)
JP (2) JP6320917B2 (ja)
KR (1) KR20140063583A (ja)
CN (1) CN103781484A (ja)
AU (1) AU2012283915B2 (ja)
BR (1) BR112014001335A2 (ja)
CA (1) CA2841964A1 (ja)
DK (1) DK2734212T3 (ja)
ES (1) ES2646226T3 (ja)
IL (1) IL230433A0 (ja)
IN (1) IN2014CN00315A (ja)
MX (1) MX350463B (ja)
MY (1) MY166036A (ja)
NO (1) NO2854815T3 (ja)
WO (1) WO2013013076A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160033796A (ko) * 2006-03-28 2016-03-28 자블린 파머슈티칼스 인코포레이티드 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
WO2008141308A2 (en) 2007-05-11 2008-11-20 Adynxx, Inc. Gene expression and pain
PL2220030T3 (pl) 2007-11-06 2016-07-29 Bioelectron Tech Corp Pochodne 4-(p-chinonylo)-2-hydroksybutanamidu do leczenia chorób mitochondrialnych
JP6251247B2 (ja) 2012-05-10 2017-12-20 エーダイニクス インコーポレイテッド 活性成分の送達のための製剤
US20140275261A1 (en) 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
PT3180434T (pt) 2014-08-15 2019-10-29 Adynxx Inc Chamarizes oligonucleotídicos para o tratamento da dor
WO2017151644A1 (en) * 2016-02-29 2017-09-08 Adynxx, Inc. Compositions and methods for pain amelioration via modification of gene expression
US20180025116A1 (en) * 2016-07-22 2018-01-25 Arizona Board Of Regents On Behalf Of University Of Arizona Clinical Event Management and Communication System
US20200027555A1 (en) * 2018-07-17 2020-01-23 Lewis Pharmaceutical Information, Inc. Patient centric drug analysis platform
BR112022013795A2 (pt) * 2020-02-18 2022-09-13 Novo Nordisk As Composição farmacêutica líquida, e, kit
CN111494446B (zh) * 2020-05-18 2021-08-17 深圳市宝安中医院（集团） 治疗胆绞痛的中药组合物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5389681A (en) 1992-10-22 1995-02-14 Ciba-Geigy Corporation Parenteral solutions for diclofenac salts
IL111184A (en) * 1993-10-08 2000-08-13 Farmarc Nederland B V Of Cito Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin
ZA949182B (en) 1993-12-02 1995-07-26 South African Druggists Ltd Pharmaceutical composition
AU2001259816A1 (en) 2000-06-22 2002-01-02 Advanced Medecine, Inc. Polyhydroxy glycopeptide derivatives
WO2003059393A1 (en) 2002-01-15 2003-07-24 Altana Pharma Ag Pantoprazole cyclodextrin inclusion complexes
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
CN1878711B (zh) * 2003-11-04 2010-12-22 奥蒂斯电梯公司 自动乘客输送机的低速运行
AU2004317520B2 (en) 2004-03-10 2011-06-09 Shimoda Biotech (Pty) Ltd Stable injectable diclofenac compositions
WO2007112274A2 (en) * 2006-03-28 2007-10-04 Javelin Pharmaceuticals, Inc. Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin
KR20160033796A (ko) * 2006-03-28 2016-03-28 자블린 파머슈티칼스 인코포레이티드 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
CN101264086A (zh) 2007-03-14 2008-09-17 南京师范大学 含有头孢克肟环糊精包合物的药物组合物及其制备方法
WO2009089269A1 (en) * 2008-01-07 2009-07-16 Javelin Pharmaceuticals, Inc. Methods of treating pain while minimizing adverse effects on platelet function
US7662858B2 (en) * 2008-05-23 2010-02-16 Aaipharma, Inc. Method of treating post-surgical acute pain

Also Published As

Publication number Publication date
EP2734212B1 (en) 2017-09-06
EP3257505A1 (en) 2017-12-20
ES2646226T3 (es) 2017-12-12
MX350463B (es) 2017-09-06
US20140221490A1 (en) 2014-08-07
IL230433A0 (en) 2014-03-31
WO2013013076A1 (en) 2013-01-24
MX2014000744A (es) 2014-05-14
NO2854815T3 (ja) 2018-04-21
EP2734212A1 (en) 2014-05-28
MY166036A (en) 2018-05-21
EP2734212A4 (en) 2014-12-24
CA2841964A1 (en) 2013-01-24
JP6320917B2 (ja) 2018-05-09
AU2012283915A1 (en) 2014-02-06
AU2012283915B2 (en) 2016-11-24
DK2734212T3 (da) 2017-11-06
JP2017110022A (ja) 2017-06-22
CN103781484A (zh) 2014-05-07
BR112014001335A2 (pt) 2017-02-21
KR20140063583A (ko) 2014-05-27
JP2014520893A (ja) 2014-08-25

Similar Documents

Publication Publication Date Title
IN2014CN00315A (ja)
CY1121041T1 (el) Μεθοδοι αγωγης παιδιατρικων ασθενων με τη χρηση δεξμεδετομιδινης
NZ610034A (en) Prevention of adverse effects caused by cd3 specific binding domains
BR112014031806A8 (pt) método para tratamento de câncer positivo para gd2
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
NZ702663A (en) Nuclear transport modulators and uses thereof
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
NZ702730A (en) Treatment of motor and movement disorder side effects associated with parkinson’s disease treatments
MX2014006762A (es) Metodos para el tratamiento de desordenes cardiovasculares.
MX364220B (es) Metodos de tratamientos de fibrosis.
NZ628433A (en) Chitosan-derived compositions
AR092103A1 (es) Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1)
MX2016000220A (es) Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
BR112012006070A2 (pt) composições e métodos para tratar distúrbios convulsivos.
MX2011007384A (es) Terapias de combinacion para trastornos neoplásticos.
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
MX359171B (es) Tratamiento para diabetes tipo i y tipo ii.
MX2014001271A (es) Tratamiento de diabetes de tipo 2 con fty720.
RU2011143250A (ru) Способ анестезии при хирургическом лечении косоглазия у детей
NZ745950A (en) Methods and compositions for treating multiple sclerosis and related disorders
MY169877A (en) Treatment of malphigia coccigera on liver cirrhosis
MX2013006633A (es) Beta-hidroxi-gamma-aminofosfonatos para el tratamiento de trastornos inmunes.